Clinically, paclitaxel (PTX) is one of most commonly prescribed therapies against a wide range of solid neoplasms.Despite its success, the clinical applicability of PTX (Taxol(R)) is severely hampered by systemic toxicities induced by Cremophor EL.While attempts to bypass the need for Cremophor EL have been developed through platforms such as AbraxaneTM, nab-technology relies heavily on the use of organic solvents, chloroform.The toxicity introduced by residual chloroform acts to limit the potential applications of AraxaneTM.